产品名称

英文名称：LY2784544

同义词

GANDOTINIB、1229236-86-5、LY2784544、LY 2784544、LY-2784544、Gandotinib (LY2784544)、3-(4-chloro-2-fluorobenzyl)-2-methyl-N-(5-methyl-1H-pyrazol-3-yl)-8-(morpholinomethyl)imidazo[1,2-b]pyridazin-6-amine、Gandotinib [USAN]、Gandotinib(LY2784544)、ANC71R916O、Gandoti

产品性质

CAS编号：1229236-86-5

分子式：C23H25ClFN7O

分子量：469.95

PubChem编号：46213929

英文别名：GANDOTINIB|1229236-86-5|LY2784544|LY 2784544|LY-2784544|Gandotinib (LY2784544)|3-(4-chloro-2-fluorobenzyl)-2-methyl-N-(5-methyl-1H-pyrazol-3-yl)-8-(morpholinomethyl)imidazo[1,2-b]pyridazin-6-amine|Gandotinib [USAN]|Gandotinib(LY2784544)|ANC71R916O|Gandoti

规格或纯度：≥98%

英文名称：LY2784544

生化机理：LY2784544 is identified as being highly selective inhibitor of JAK2 mutant V617F and has advanced into human clinical trials for the treatment of several myeloproliferative disorders.

储存温度：-20°C储存

运输条件：超低温冰袋运输

备注：卖完停产，不再备货

产品介绍：LY2784544是一种有效的JAK2抑制剂，IC50为3 nM，作用于JAK2V617F有效，比作用于JAK1和JAK3选择性高8和20倍。Phase 2。A selective inhibitor of JAK2 mutant V617F.LY2784544 is a potent JAK2 inhibitor with IC50 of 3 nM, effective in JAK2V617F, 8- and 20-fold selective versus JAK1 and JAK3. Phase 2.A selective inhibitor of JAK2 mutant V617F.

ALogP：3.8

IUPAC Name：3-[(4-chloro-2-fluorophenyl)methyl]-2-methyl-N-(5-methyl-1H-pyrazol-3-yl)-8-(morpholin-4-ylmethyl)imidazo[1,2-b]pyridazin-6-amine

INCHI：InChI=1S/C23H25ClFN7O/c1-14-9-21(29-28-14)27-22-11-17(13-31-5-7-33-8-6-31)23-26-15(2)20(32(23)30-22)10-16-3-4-18(24)12-19(16)25/h3-4,9,11-12H,5-8,10,13H2,1-2H3,(H2,27,28,29,30)

InChi Key：SQSZANZGUXWJEA-UHFFFAOYSA-N

Canonical SMILES：CC1=CC(=NN1)NC2=NN3C(=C(N=C3C(=C2)CN4CCOCC4)C)CC5=C(C=C(C=C5)Cl)F

Isomeric SMILES：CC1=CC(=NN1)NC2=NN3C(=C(N=C3C(=C2)CN4CCOCC4)C)CC5=C(C=C(C=C5)Cl)F

PubChem CID：46213929

CAS Registry No.：1229236-86-5

ChEMBL Ligand：CHEMBL2107823

溶解性：DMSO 94 mg/mL (200.02 mM); Water <1 mg/mL (<1 mM); Ethanol 9 mg/mL (19.15 mM)

产品包装